Achievements and goals of the EORTC Invasive Fungal Infections Group

European Journal of Cancer

Volumn 38, Issue SUPPL. 4, 2002, Pages

  Pauw, B E ^a   Herbrecht, R ^a,c   Meunier, F ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Antifungal agents; Empirical therapy; Fungal infections; Prevention; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NYSTATIN; VORICONAZOLE;

ARTICLE; CARCINOMA; CLINICAL TRIAL; FATALITY; HEALTH CARE ORGANIZATION; HUMAN; INFECTION PREVENTION; MYCOSIS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; EUROPE; HUMANS; INTERNATIONAL AGENCIES; MEDICAL ONCOLOGY; MYCOSES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RESEARCH;

EID: 0036175967     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
2. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients. Diagnosis and therapeutic outcome
3. Impact of previous aspergillosis on the outcome of bone marrow transplantation
4. Invasive Aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma
5. International conference for the development of a consensus on the management and prevention of severe candidal infections
6. Reliability of clinical research on invasive fungal infections: A systematic basic review of the literature
7. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplantation: An international consensus
8. An EORTC IFICG phase III randomized study comparing fluconazole to itraconazole in non neutropenic cancer patients with oropharyngeal candidiasis
9. An EORTC multicenter randomised trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
10. EORTC-IFICG Phase II study on liposomal nystatin in patients with invasive aspergillosis (IA) infections, refractory or intolerant to conventional/lipid ampho B. (AB)
11. Practical modalities for prevention of fungal infections in cancer patients